Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Enveric Biosciences, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +4 vs. Q1 2021
- Shares held
- 1.15M
- +33.6K (+3.0%) vs. Q1 2021
- Total value
- $2.72M
- −$700.0K (−20.5%) vs. Q1 2021
- New holders
- 7
- 7 more added
- Sold out
- 3
- 3 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $736.8K |
| Q1 2026 | 11 | $106.6K |
| Q4 2025 | 11 | $87.7K |
| Q3 2025 | 11 | $232.6K |
| Q2 2025 | 14 | $283.2K |
| Q1 2025 | 15 | $344.7K |
| Q4 2024 | 19 | $386.7K |
| Q3 2024 | 17 | $337.2K |
| Q2 2024 | 17 | $307.3K |
| Q1 2024 | 18 | $488.4K |
| Q4 2023 | 15 | $635.8K |
| Q3 2023 | 15 | $518.3K |
| Q2 2023 | 14 | $631.1K |
| Q1 2023 | 13 | $382.4K |
| Q4 2022 | 12 | $356.8K |
| Q3 2022 | 12 | $623.0K |
| Q2 2022 | 27 | $1.99M |
| Q1 2022 | 31 | $3.61M |
| Q4 2021 | 31 | $4.45M |
| Q3 2021 | 24 | $4.64M |
| Q2 2021 | 18 | $2.72M |
| Q1 2021 | 14 | $3.42M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Enveric Biosciences, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 509,482 | $1.21M | 0.00% | −54,038−9.6% | Reduced |
| Vanguard Group Inc | 181,583 | $432.0K | 0.00% | +600+0.3% | Added |
| Geode Capital Management, LLC | 98,894 | $235.0K | 0.00% | +35,800+56.7% | Added |
| State Street Corp | 88,886 | $212.0K | 0.00% | +88,886 | New |
| UBS Group AG | 67,396 | $160.0K | 0.00% | +35,924+114.1% | Added |
| Virtu Financial LLC | 52,943 | $126.0K | 0.01% | −128,311−70.8% | Reduced |
| Northern Trust Corp | 36,504 | $87.0K | 0.00% | +25,393+228.5% | Added |
| Engineers Gate Manager LP | 30,380 | $72.0K | 0.00% | −8,715−22.3% | Reduced |
| Penserra Capital Management LLC | 26,986 | $52.0K | 0.00% | +26,986 | New |
| Creative Planning | 17,577 | $42.0K | 0.00% | +17,577 | New |
| Citadel Advisors LLC | 13,085 | $31.0K | 0.00% | +13,085 | New |
| Signaturefd, LLC | 7,000 | $17.0K | 0.00% | +7,000 | New |
| Wells Fargo & Company | 5,696 | $14.0K | 0.00% | +4,813+545.1% | Added |
| Tower Research Capital LLC (TRC) | 5,134 | $12.0K | 0.00% | +5,134 | New |
| Advisor Group Holdings, Inc. | 3,000 | $7.00K | 0.00% | +1,900+172.7% | Added |
| FNY Investment Advisers, LLC | 3,040 | $7.00K | 0.00% | +3,000+7,500.0% | Added |
| Morgan Stanley | 1 | $0 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 1 | $0 | 0.00% | +1 | New |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −21,021−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,400−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −10−100.0% | Sold out |